01993nas a2200397   4500000000100000008004100001260001300042653001600055653002600071653002400097653003700121653001100158653001600169653001100185653001400196653001300210653001200223653002500235653000900260653002500269653003000294653001500324653001600339100001400355700001500369700001100384700001600395700001400411700001600425245016100441856004100602300001100643490000700654520092000661022001401581       1990                            d  c1990 Dec10aAge Factors10aAntibodies, Bacterial10aAntigens, Bacterial10aDemocratic Republic of the Congo10aFemale10aGlycolipids10aHumans10aIncidence10aLepromin10aleprosy10aLongitudinal studies10aMale10aMycobacterium leprae10aPredictive Value of Tests10aPrevalence10aSex Factors1 aGroenen G1 aPattyn S R1 aGhys P1 aTshilumba K1 aKuykens L1 aColston M J00aA longitudinal study of the incidence of leprosy in a hyperendemic area in Zaire, with special reference to PGL-antibody results. The Yalisombo Study Group.  uhttp://ila.ilsl.br/pdfs/v58n4a01.pdf  a641-500 v583 a<p>Between 1984 and 1988, yearly surveys for leprosy were done among the 1500 people living in a previous leprosy segregation village in Zaire. In 1984 lepromin tests and phenolic glycolipid (PGL) antibody tests were done in a significant part of the population. The prevalence of the disease at that time was 16.1%, the proportion of multibacillary cases was 11.3% overall and 22% among active cases. Prior to 1984, 23% of paucibacillary cases and 56% of multibacillary cases had presented themselves spontaneously to the Leprosy Service. The exposure to the infection is uniform, but there is a suggestion of family clustering of cases. In spite of a rapidly bactericidal treatment of all known cases in 1984 and thereafter, the annual incidence of 0.34% did not decrease during the 4 years of the study. The PGL antibody test did not contribute to the diagnosis, classification or prognosis of the disease.</p>
  a0148-916X